Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lopinavir/ritonavir (Primary) ; Lamivudine/abacavir; Lamivudine/zidovudine
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms LIVING

Most Recent Events

16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
16 Feb 2022 Data from this study used to develop a PK-PD model from Kenya and Uganda CLHIV to assess ABC exposures across WBs presented at the 29th Conference on Retroviruses and Opportunistic Infections
17 May 2019 Status changed from active, no longer recruiting to completed.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight